Literature DB >> 28109005

The membrane-bound O-acyltransferase domain-containing 7 variant rs641738 increases inflammation and fibrosis in chronic hepatitis B.

Khaled Thabet1,2, Henry Lik Yuen Chan3, Salvatore Petta4, Alessandra Mangia5, Thomas Berg6, Andre Boonstra7, Willem P Brouwer7, Maria Lorena Abate8, Vincent Wai-Sun Wong3, Maiiada Nazmy2, Janett Fischer6, Christopher Liddle1, Jacob George1, Mohammed Eslam1.   

Abstract

Chronic hepatitis B (CHB) is characterized by hepatic inflammation that promotes progression to cirrhosis and predisposes to the development of hepatocellular carcinoma (HCC). Subtle interindividual genetic variation as well as viral and environmental factors interact to determine disease progression between individuals. Recently, the rs641738 membrane-bound O-acyltransferase domain-containing 7 (MBOAT7) polymorphism was demonstrated to influence histological liver damage in alcoholic liver disease, nonalcoholic fatty liver disease, and hepatitis C, but no data are available for CHB. We evaluated rs641738 influence on disease severity in a cohort of 1,101 patients with CHB. Forty-two patients underwent gene expression analysis to assess the functional consequences of rs641738 on hepatic MBOAT7 expression. The minor allele (T) of rs641738 was associated with greater inflammation (odds ratio [OR], 1.45; 95% confidence interval [CI], 1.06-1.95; P = 0.001) and fibrosis (OR = 1.31; 95% CI, 1.19-1.92; P = 0.01). Risk allele frequency in whites (0.43) was greater than in Chinese (0.24), translating to a larger size effect in the former. The rs641738 (T) allele was associated with lower hepatic MBOAT7 expression (P = 0.008), and the latter was associated with serum liver enzymes and inflammation. Neither patatin-like phospholipase domain-containing protein 3 rs738409 nor transmembrane 6 superfamily member 2 rs58542926 polymorphisms influenced disease severity.
CONCLUSION: In patients with CHB, MBOAT7 rs641738 influences hepatic inflammation and fibrosis stage. (Hepatology 2017;65:1840-1850).
© 2017 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28109005     DOI: 10.1002/hep.29064

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  27 in total

Review 1.  Association of metabolic dysfunction-associated fatty liver disease with kidney disease.

Authors:  Ting-Yao Wang; Rui-Fang Wang; Zhi-Ying Bu; Giovanni Targher; Christopher D Byrne; Dan-Qin Sun; Ming-Hua Zheng
Journal:  Nat Rev Nephrol       Date:  2022-01-10       Impact factor: 28.314

Review 2.  Detangling the interrelations between MAFLD, insulin resistance, and key hormones.

Authors:  Shreya C Pal; Mohammed Eslam; Nahum Mendez-Sanchez
Journal:  Hormones (Athens)       Date:  2022-08-03       Impact factor: 3.419

Review 3.  Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight.

Authors:  Mohammed Eslam; Hashem B El-Serag; Sven Francque; Shiv K Sarin; Lai Wei; Elisabetta Bugianesi; Jacob George
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2022-06-16       Impact factor: 73.082

4.  The rs626283 Variant in the MBOAT7 Gene is Associated with Insulin Resistance and Fatty Liver in Caucasian Obese Youth.

Authors:  Giuseppina R Umano; Sonia Caprio; Anna Di Sessa; Naga Chalasani; Daniel J Dykas; Bridget Pierpont; Allen E Bale; Nicola Santoro
Journal:  Am J Gastroenterol       Date:  2018-02-27       Impact factor: 10.864

5.  Obesity-linked suppression of membrane-bound O-acyltransferase 7 (MBOAT7) drives non-alcoholic fatty liver disease.

Authors:  Robert N Helsley; Venkateshwari Varadharajan; Amanda L Brown; Anthony D Gromovsky; Rebecca C Schugar; Iyappan Ramachandiran; Kevin Fung; Mohammad Nasser Kabbany; Rakhee Banerjee; Chase K Neumann; Chelsea Finney; Preeti Pathak; Danny Orabi; Lucas J Osborn; William Massey; Renliang Zhang; Anagha Kadam; Brian E Sansbury; Calvin Pan; Jessica Sacks; Richard G Lee; Rosanne M Crooke; Mark J Graham; Madeleine E Lemieux; Valentin Gogonea; John P Kirwan; Daniela S Allende; Mete Civelek; Paul L Fox; Lawrence L Rudel; Aldons J Lusis; Matthew Spite; J Mark Brown
Journal:  Elife       Date:  2019-10-17       Impact factor: 8.140

Review 6.  Genetic contributions to NAFLD: leveraging shared genetics to uncover systems biology.

Authors:  Mohammed Eslam; Jacob George
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-10-22       Impact factor: 46.802

7.  E167K polymorphism of TM6SF2 gene affects cell cycle of hepatocellular carcinoma cell HEPA 1-6.

Authors:  Shuixian Du; Linlin Lu; Yingxia Miao; Wenwen Jin; Changfei Li; Yongning Xin; Shiying Xuan
Journal:  Lipids Health Dis       Date:  2017-04-13       Impact factor: 3.876

8.  Lack of evidence supporting a role of TMC4-rs641738 missense variant-MBOAT7- intergenic downstream variant-in the Susceptibility to Nonalcoholic Fatty Liver Disease.

Authors:  Silvia Sookoian; Diego Flichman; Martin E Garaycoechea; Carla Gazzi; Julio San Martino; Gustavo O Castaño; Carlos J Pirola
Journal:  Sci Rep       Date:  2018-03-23       Impact factor: 4.379

9.  MBOAT7-TMC4 rs641738 Is Not Associated With the Risk of Hepatocellular Carcinoma or Persistent Hepatitis B Infection.

Authors:  Peng Wang; Ying Li; Lu Li; Rong Zhong; Na Shen
Journal:  Front Oncol       Date:  2021-05-25       Impact factor: 6.244

10.  Serum levels of caspase-cleaved cytokeratin 18 (CK18-Asp396) predict severity of liver disease in chronic hepatitis B.

Authors:  Juan Li; Auke P Verhaar; Qiuwei Pan; Robert Jacobus de Knegt; Maikel P Peppelenbosch
Journal:  Clin Exp Gastroenterol       Date:  2017-08-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.